AKT1 and cancer: Our study further sheds light on the resistant mechanisms of GBM to targeted therapies, providing compelling rationale for the combined inhibition of PI3K/Akt and mTORC2 as a promising “combinatorial targeted therapy” for targeting cancer cell metabolism [83] (Figure 4).